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Comparison of mifepristone combination with misoprostol and misoprostol
alone in the management of intrauterine death
Condensation e misoprostol and mifepristone combination is more effective
than misoprostol alone in the management of intrauterine death
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Accepted 15 January 2011AbstractObjectives: To compare the efficacy and safety of misoprostol and mifepristone combination with misoprostol alone in management of intra-
uterine death.
Materials and Methods: It is a prospective study carried out in 40 pregnant women admitted with intrauterine death after 28 weeks of gestation at
a tertiary care referral centre divided into two groups of 20 each. Every alternate patient was assigned Group I and Group II. Group I
(combination group) e the women received 200 mg of mifepristone; and after 36 hours, misoprostol was administered orally (100 mg if
pregnancy was <37 weeks and 50 mg if pregnancy was >37 weeks) for every 3 hour till they went into active labor for a maximum of four doses.
Group II (misoprostol group) eWomen received oral misoprostol (100 mg if pregnancy was <37 weeks and 50 mg if pregnancy was >37 weeks)
for every three hours till she went into active labor for maximum of four doses.
Primary outcome measures were achievement of successful induction and induction delivery interval (IDI). Women who did not deliver after
four doses of misoprostol were considered as failure. In all the women, bishop score before the start of mifepristone and misoprostol, induction
delivery interval, and adverse effect of the drug were noted. Data were analyzed by using Student t test and Chi-square test.
Results: In the Group I, 60% of women, delivered with mifepristone alone. The rest of the patients [8 (40%)] had significant improvement of the
bishop score after 36 hour. Parity, gestation, and bishop score did not affect the success of induction in the Group I. IDI was significantly less in
the Group I (6.72  3.34) as compared with that of the Group II (11.81  6.33). Parity, gestation, and bishop score did not affect the IDI in the
two groups. Number of doses of misoprostol required were significantly less in patients who were pretreated with mifepristone.
Conclusion: Combination of mifepristone and misoprostol is more effective than the misoprostol alone for induction of labor in women with
intrauterine death.
Copyright  2011, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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demise, but in about 25e35% of cases, the cause remains
unknown [1].
Intrauterine death can lead to various complications like
psychological upset and intrauterine infections. If dead fetus
is retained in uterus for more than 4 weeks, it can lead to
consumptive coagulopathy and disseminated intravascular
coagulation [2]. When the fetal death occurs, spontaneous
expulsion will usually occur in most cases i.e. in about 80% ofcs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Distribution of various parameters in two groups
Parameter Group I Group II p, t
Age (y) 22.85  2.79 23.6  3.25 0.05, j0.782j
Parity 0.65  0.81 0.55  0.94 0.05, j0.359j
Gestation 33.35  3.63 34.60  3.94 0.05, j1.043j
BMI 20  1.17 19.95  1.10 0.05, j0.139j
Initial bishop score 1.45  1.60 2.1  1.20 0.05, j0.25j
Induction delivery interval 6.72  3.34
(8 patients)
11.81  6.33 0.05, j2.73j
No. of doses of misoprostol 1.6  0.92 3  0.95 0.01, j3.32j
Data were represented as mean  standard deviation.
BMI ¼ body mass index.
Table 2
Correlation of successful induction after mifepristone with bishop score,
parity, and gestation age
Parameter
(n)
Successful
(12 women)
Unsuccessful
(8 women)
p
Parity Primi (9) 5 4 p > 0.05, c20.134
Multi (11) 7 4
Gestation <34 wk (10) 4 6 p > 0.05, c21.080
>34 wk (10) 8 2
Bishop
score
<3 (16) 8 8 p > 0.05, c23.33
>3 (4) 4 0
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the request of women to relieve emotional distress.
Various methods have been tried in the management of
intrauterine death. Before the introduction of the prostaglan-
dins, women with intrauterine death were managed by giving
repeated high doses of estrogens [3], intra amniotic injection
of hypertonic solutions [4], use of hygroscopic tents [5],
bougies, catheter, and balloon [6,7], or more frequently with
repeated high dose infusion of oxytocin [8,9].
Now the prostaglandins have revolutionized the management
of intrauterine death. They can be used by oral, sublingual,
intravenous, intramuscular, vaginal, and rectal routes. Nausea
and vomiting is the main side effect of prostaglandins. The role
of antiprogestin, mifepristone for uterine priming was first
reported by Cabrol et al [10], who reported successful induction
of labor using mifepristone 200 mg 12-hourly for 2 days.
Subsequently it was observed that combination of mifepristone
and misoprostol for induction of labor in late intrauterine death
is more effective and safe regimen and the induction to delivery
interval is shorter than the studies using mifepristone or
misoprostol alone [11]. Mifepristone, an antiprogestrone
steroid, increases uterine activity, sansitizes the myometrium to
prostaglandins action, and induces cervical ripening with
minimal side effects. It is of great interest in reducing duration
of termination and increasing comfort for the patient. Keeping
this fact in mind the present study was planned.
Material and methods
The present prospective study was carried out in 40 preg-
nant women admitted with intrauterine death after 28 weeks of
gestation in labor ward of department of Obstetrics & Gyne-
cology at a Tertiary Care Referral Center after ethical clear-
ance. The women were divided randomly, alternatively, into
two groups of 20 each, the patient came first was assigned
Group I, the next patient Group II, then Group I, and so on.
Total number of patients was decided by power analysis.
Group I (combination group) e it included 20 women, who
were induced with mifepristone and misoprostol combination.
The women received 200 mg of mifepristone; and after 36
hours, misoprostol was administered orally (100 mg if preg-
nancy was <37 weeks and 50 mg if pregnancy was>37 weeks)
for every 3 hours, till they went into active labor for
a maximum of four doses.
Group II (Misoprostol group) e It included 20 women who
received oral misoprostol (100 mg if pregnancy was<37 weeks
and 50 mg if pregnancy was>37 weeks) 3 hourly, till she went
into active labor for a maximum of four doses. Every alternate
patient was assigned the respective group.
Women with previously scarred uterus, multiple gestation,
glaucoma, asthma, epilepsy, heart disease, and grand multipara
were excluded from the study.
Primary outcome measures were achievement of successful
induction and induction delivery interval. Success of induction
was defined as vaginal delivery occurring within 36 hours of
administration of mifepristone and within 24 hours of admin-
istration of first dose of misoprostol.Women who did not deliver after four doses of misoprostol
were considered as failure of regimen. In all the women details
of the demographic profile, bishop score before the start of
mifepristone and misoprostol, induction delivery interval, and
adverse effect of the drug were noted. The induction delivery
interval and success of induction was also correlated with
bishop score [<3 (very poor bishop) and 0.3] at the start of the
treatment in the two groups. Data were analyzed by using
Student t test and Chi-square test.Results
Results are shown in Tables 1e3. Both the groups were
comparable in terms of age, parity, gestation age, and bishop
score (Table 1). There were 45% primigravida and 55%
multigravida in the Group I and 70% primigravida and 30%
multigravida in the Group II. Most patients (80%) had bishop
score 0e3 in the two groups. In the Group I 60% of (12)
women, delivered with mifepristone only, thus had 60%
success of induction. Success of induction with mifepristone
was not related to age, parity, and bishop score (Table 2,
p > 0.05). In the Group I, there were four patients who had
bishop score>3 and all of these patients delivered with
mifepristone, whereas 16 patients had bishop score 0e3 of
which only 8 patients (50%) delivered after giving mifepris-
tone. The rest of the 8 patients, who did not deliver with
mifepristone, had bishop score 0 before the start of treatment
and 2.63  2.26 after 36 hours of treatment. The change is
highly significant ( p < 0.01). On correlating the success of
induction in the Group I (12 patients), with parity, gestation,
Table 3
Correlation of IDI (h) in the two groups with parity, gestation, and bishop score
Parameter (n) Group I IDI (h) Group II IDI (h) p, t
Bishop score <3 8.07  3.47 (4) 13.41  6.29 (14) 0.128 (>0.05), j1.605j
>3 4.92  2.81 (4) 8.06  5.07 (6)
Gestation <34 wk 7.60  2.98 (6) 11.69  6.49 (10) 0.172 (>0.05), j1.438j
>34 wk 3.2  2.54 (2) 11.93  6.51 (10)
Parity Primi 8.65  3.19 (4) 12.71  6.03 (14) 0.220 (>0.05), j1.276j
Multi 4.35  2.02 (4) 9.72  7.09 (6)
IDI ¼ induction delivery interval.
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For induction delivery interval (IDI) evaluation, eight women
were left in the Group I, IDI was significantly less in the
Group I as compared with that of the Group II ( p < 0.05)
(Table 1). On comparing the IDI in the two groups in term of
parity, gestation, and bishop score, there was no significant
difference (Table 3).
All the women in the study had success of induction i.e.
delivered within 24 hours after first dose of misoprostol. As far
as the side effects are concerned, only two women experienced
vomiting and diarrhea, one each with mifepristone (Group I).
With misoprostol, the side effects like nausea, vomiting,
headache, diarrhea, and fever were experienced by 10.75%,
25%, 14.29%, 7.15%, and 17.86% of women, respectively.
Discussion
The study was carried out to find the IDI in patients with
intrauterine death who were treated with misoprostol alone or
combination of mifepristone and misoprostol. The primary
outcome measure was the achievement of successful induction
and induction delivery interval. The success of induction was
defined as vaginal delivery occurring within 36 hours of
administration of mifepristone or within 24 hours of admin-
istration of first dose of misoprostol.
Mifepristone is an antiprogestational steroid, which induces
cervical ripening and increases uterine activity, thus leading to
the expulsion of fetus [12,13]. In the Group I 12/20 (60%)
patients achieved successful induction with mifepristone alone,
within 36 hours. Similar results were also shown by other
authors [14,15]. In 1989, Padayachi et al [14] studied mife-
pristone in a dosage of 400 mg/d to induce labor in patients
with intrauterine death in late pregnancy and found that 8 of 12
patients (66.7%) delivered within 72 hours of treatment,
whereas only 2 of 12 patients (16.7%) delivered, who were
treated with placebo .In 1990, Cabrol et al [15] studied 94
women with intrauterine death and found that mifepristone
given 200 mg 3 a day for 2 days resulted in 29 of 46 (63%)
patients delivering within 72 hours of start of treatment
compared with only 17% patients delivering within 72 hours,
who were treated with placebo.
In present study, the mean induction delivery interval was
6.72 [3.34 (1.4e13)] and 11.81 [6.33 (4e25.30)] hours in the
Group I and Group II, respectively (Table 1) and the difference
was highly significant. The result of our study is not compa-
rable to the study of Vayrynen et al, who studied 130 womenwith intrauterine fetal death (21e42 weeks of gestation) 16. In
their study, 82 women received 100 g misoprostol at 4-hour
interval and 48 women received 200 mg mifepristone followed
19 hours later by misoprostol 25 g at 4-hour interval and found
that induction to delivery interval did not differ between the two
groups (13.3 hours vs. 12.8 hours). The reason for the similar
induction delivery interval in both groups may be the lower
dose of misoprostol as they have used only 25 g misoprostol in
group which was pretreated with mifepristone, whereas 100 g
misoprostol in another group which was not pretreated with
mifepristone.
In 2002, Wagaarachchi et al [11] studied the combination of
mifepristone and misoprostol in 96 patients with intrauterine
death and found that IDI was shorter with increasing gestation
(p ¼ 0.001). In the present study, induction delivery interval
was not affected by the gestation, parity and bishop (Table 2).
The mean number of doses of misoprostol required in the
Group I and Group II was 1.6(0.92) and 3(0.95), respectively
(p < 0.01, highly significant, Table 1), in present study. The
similar results were also noted by Vayrynen et al, in 2007, who
found that doses of misoprostol needed were less in the group
which was pretreated with mifepristone (p ¼ 0.0028) [16].
So, both mifepristone in combination with misoprostol and
misoprostol alone achieved successful induction in women
with intrauterine fetal death. Mifepristone alone led to delivery
of baby in 60% of patients in the Group I. Mifepristone led to
significant improvement in bishop score in patients who were
not delivered by this drug. The combination therapy led to
short induction delivery interval than that of misoprostol
alone. In addition, the number of doses of misoprostol required
was less in patients who were pretreated with mifepristone.
To conclude, combination therapy of mifepristone and
misoprostol is more effective than the misoprostol alone for
induction of labor in women with intrauterine fetal death.
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